Background
Type 2 diabetes mellitus (T2DM) refers to a chronic health condition [
1]. But it has reached alarming rates, with an incidence of 1 in 10, across the globe [
2]. Now 537 million adults are living with diabetes, and this number would rise to 643 million by 2030 [
3]. Cardiovascular diseases (CVDs) are common diabetes-related complications and contribute to more than one-half of all deaths in people affected by T2DM [
4]. Atherosclerotic CVDs, such as coronary heart disease, cerebrovascular disease, and peripheral arterial disease, are the major cause of mortality from diabetes complications [
5]. Heart failure is another main cause of mortality for individuals with diabetes. The 5-year mortality rate for diabetic patients after myocardial infarction, as high as 50%, is twice that of nondiabetic patients [
6]. Controlling individual cardiovascular complications has shown great efficiency in preventing mortality or slowing disease progression in people with diabetes [
7]. Risk factors for T2DM and the related microvascular complications comprise a combination of both genetic and metabolic factors [
8]. Given the recognition of diabetes as the global burden and the risk of CVDs with diabetes, the urgent need for early detection of T2DM and effective prediction of CVDs in T2DM seems to be emerging.
Long noncoding RNAs (LncRNAs), a class of transcripts longer than 200 nucleotides, have no protein-coding potential [
9]. However, they have been verified to implicate multiple cellular transcriptions, resulting in a profound impact on the dysregulation of growth-promoting, pro-fibrotic, and pro-apoptotic genes in target organs [
10]. It is increasingly recognized that lncRNAs can actively participate in the pathogenesis of diverse metabolic and cardiovascular diseases, such as T2DM and CVDs [
11,
12]. In recent years, lncRNAs have been widely investigated in various diseases, including T2DM, as a novel type of biomarkers. Li et al. has selected five upregulated lncRNAs as potential biomarkers by microarray analysis and verified the high diagnostic value of ENST00000550337.1 for pre-diabetes and T2DM [
13]. Another example is HOTAIR, which is aberrant in serum of person with T2DM as a diagnostic factor for T2DM and a prediction for chronic complications of T2DM [
14]. Considering that current treatment for many diabetic complications has not yet been fully effective, an exploration of epigenetic mechanisms may provide a novel and valuable insight into the pathophysiology of diabetic CVDs. For instance, recent advances in lncRNA DCRF have yielded information about its contribution to increasing cardiomyocyte autophagy in diabetic cardiomyopathy [
15].
FGD5-AS1 has been associated with cardiovascular diseases [
16,
17]. And a microarray profiling of muscle tissues from insulin-sensitive and insulin-resistant individuals showed that FGD5-AS1 was a susceptibility gene for T2D [
18]. Herein, we determined the dysregulated expression of FGD5-AS1 in T2DM individuals, with or without CVDs, and investigated its diagnostic capability for T2DM and related CVDs.
Methods
Study design and population
A total of 200 patients were recruited in this study, including 100 patients with T2DM without CVDs, and 100 patients with T2DM and progress in CVDs. In addition, 100 healthy subjects, who had no medical history of diabetes and CVDs, were recruited. The study protocol was approved by the scientific ethical committee of Weihai Municipal Hospital. Before inclusion into the study, written informed consent was obtained from each enrolled patient and healthy subject following the Declaration of Helsinki. T2DM was diagnosed according to criteria formulated by the American Diabetes Association. The diagnosis of CVDs was conducted following the current national guidelines by experienced cardiologists [
19,
20].
Measurement of plasma lncRNA/mRNA levels
Venous blood samples were drawn directly into Tempus™ Blood RNA Tube (Life Technologies, Austin, USA), and immediately vortex for 10 s. Then stabilized blood was transferred to 50-mL sterile conical tubes, and total RNA was isolated, purified, and stored by Tempus™ Spin RNA Isolation Kit (Life Technologies, Austin, USA) following the user guide. Extracted RNA was converted to cDNA by using the RT2 PreAMP cDNA Synthesis Kit (Qiagen). cDNA was synthesized from total RNA using HiScript II 1st Strand cDNA synthesis kit (Vazyme, China). The primers for qRT-PCR were: 5′-CGTGGAGAAGAATTGGGC-3′ (Forward) and 5′-CGTGGAGAAGAATTGGGC-3′ (Reverse) for FGD5-AS1; 5'-AACGGATTTGGTCGTATTG-3' (Forward) and 5'-GGAAGATGGTGATGGGATT-3' (Reverse) for GAPDH. qRT-PCR was performed with FastStart Universal SYBR Green Master (Rox) (Roche, Indianapolis, USA) at a 7500 Real-Time PCR System (Applied Biosystems, Waltham, USA). Data were analyzed by the 2−ΔΔCt method normalized relative to the amount of GAPDH.
Cell culture
AC16 (human primary ventricular cardiomyocytes) was purchased from Bluefcell (Shanghai, China) and cultured in DMEM (HyClone, Beijing, China) supplemented with 10% FBS (HyClone, Victoria, Australia). HA-VSMC (Human aortic vascular smooth muscle cell) was from Procell Life (Wuhan, China) and grown in its special medium (Procell Life). The culture condition for cells in the control group (mock) was routine, at 37 °C in 5% CO2. For the high glucose-induced group (HG), cells were culture in the presence of 30 mmol/L of glucose for an indicated time at 37 °C in 5% CO2.
Overexpressed FGD5-AS1 was produced with pcDNA3.1 termed as ov-FGD5-AS1 and the negative control pcDNA 3.1 vector (ov-NC) with inserted scrambled sequences were purchased from GenePharma (Shanghai, China.). The transfection was conducted by using Lipofectamine 3000 Reagent (Invitrogen, USA).
Cell growth assay
For the viability experiment, Cell Counting Kit 8 (WST-8/CCK8) (ab228554, Abcam, Cambridge) was used. AC16 and HA-VSMC cells were seeded at a density of 4 × 103 cells/well in 96-well plates. The number of the viable cells was determined at 0, 24, 48, 72 h according to the user guide.
Calcification assays
HA-VSMC cells or transfected HA-VSMC cells were cultured with 30 mmol/L glucose for 14 days. Then, cells were washed, scraped into a solution, and lysed with Cell lysis buffer for Western and IP without inhibitors (Beyotime Biotechnology, Shanghai, China). Cell lysates were measured for alkaline phosphatase (ALP) activity using an Alkaline Phosphatase Assay Kit (Beyotime Biotechnology, Shanghai, China) and for osteocalcin secretion using an osteocalcin assay kit (Jiancheng, Nanjing). ALP activity and osteocalcin secretion were normalized to the total cellular protein of the cellular layers and then normalized to that of the control [
21].
Assessment of cell apoptosis and myocardial cell fibrosis
For apoptosis assay, non-transfected or transfected cells were cultured with 30 mmol/L glucose for 24 h. For assessment of cell fibrosis, AC16 cells were cultured with the complete medium including 30 mmol/L glucose for 48 h. Then, RNA in cells was extracted using Invitrogen TRIzol (California, USA). The expression of apoptosis markers, caspase-3, Bcl-2, and Bax mRNA, and fibrosis-related mRNAs (Collagen-1 and Collagen-3) was checked by RT-qPCR using the 2−ΔΔCt method.
Statistical analysis
The normality of the data set was assessed by D’Agostino and Pearson omnibus normality test. Categorical variables were expressed as the number of cases and compared using the chi-square test. Continuous variables were shown as mean ± standard deviation (SD). The normally distributed continuous variables were analyzed using the student’s t test or one-way ANOVA as appropriate. Whereas non-normally distributed continuous variables were compared using the non-parametric Mann–Whitney U test or Kruskal–Wallis test as appropriate. P value of < 0.05 was statistically significant. The correlation of FGD5-AS1 level with other key variables was accessed using Pearson correlation analysis. Receiver operating characteristic (ROC) curves were plotted to display the diagnostic value of the FGD5-AS1 level. Data statistical analyses were performed using IBM SPSS Statistics 23 or GraphPad Prism 7.
Discussion
The ever-increasing incidence of diabetes worldwide has ratcheted up the risk for various associated complications, including CVDs. A high percentage of individuals with T2DM would develop CVDs, such as atherosclerosis, stroke and hypertension. Over the recent years, the trend in mortality and CVDs increased among both diabetics and non-diabetics. A greater emphasis on diabetic control and cardiovascular risk factors is most likely to reverse this encouraging trend. In the past decades, several common biochemical mechanisms and genetic factors have been implicated in the pathology of diabetes [
22]. Recently, lncRNA-mediated mechanisms have also been implicated in T2DM and the progression of T2DM-related CVDs because crosstalk between the actions of various diabetogenic factors can amplify and perpetuate the expression of related genes [
23]. Hence, further, unscramble of these novel epigenetic mechanisms could help improve the efficacy of early diagnosis and available therapies for T2DM and its subsequent CVDs.
In this study, FGD5-AS1 was identified as a lncRNA closely associated with T2DM and the development of CVDs. FGD5-AS1 has been previously detected in many cancers, such as glioblastoma, oral cancer [
24‐
26]. It was also identified as one of eight candidate lncRNAs associated with dilated cardiomyopathy disease which is a common cause of heart failure [
17]. In another lncRNA co-expression network analysis, FGD5-AS1 was differently expressed, associated with acute myocardial infarction-related signaling pathways, such as protein amino acid phosphorylation, regulating transcription, and signal transduction, and identified as a key lncRNA for acute myocardial infarction [
27]. Here, we found FGD5-AS1 was downregulated in T2DM and T2DM-complicated CVDs, which was in line with the results from GEO DataSets. This dysregulation of FGD5-AS1 implies a potential role in T2DM and its related CVDs. Therefore, we tried to explore the diagnostic value of FGD5-AS1 in T2DM and its related CVDs. The correlation analysis revealed that FGD5-AS1 downregulation was closely interconnected with CVDs related factors, such as BMI, systolic blood pressure, diastolic blood pressure, fasting glucose, 2-h postprandial blood glucose, HbA1c, HDL-cholesterol, and usCRP.
ROC curves between healthy and T2DM with or without CVDs confirmed the great value of FGD5-AS1 in T2DM diagnosis, while the ROC curve between T2DM with CVDs and without CVDs showed distinguishing potential of FGD5-AS1 in CVDs progression. So FGD5-AS1 has potential in the diagnosis of T2DM and prediction of the CVDs.
FGD5-AS1 is an antisense RNA of FGD5, which belongs to the Rho guanine nucleotide exchange factor (Rho GEF) family complicating in various cellular processes [
28]. FGD5-AS1 has been discovered to attenuate hypoxia-induced oxidative stress and apoptosis in human cardiomyocytes [
29]. FGD5-AS1 has also exhibited an effect of extenuating oxygen–glucose deprivation and simulated reperfusion damage by increasing neuron proliferation but reducing neuron apoptosis [
30]. In this study, FGD5-AS1 displayed an effect on the proliferation and apoptosis of human primary ventricular cardiomyocytes (AC16) and aortic vascular smooth muscle cells (HA-VSMC). Specifically, overexpressed FGD5-AS1 could accelerate growth and block apoptosis in AC16 cells, which may help relieve cardiomyocyte hypertrophy and apoptosis. FGD5-AS1 was also reported to increase the viability of C20/A4 cells but prevent apoptosis, thereupon then retard osteoarthritis development [
31]. Combined with the report that FGD5‑AS1 modulated hypoxic injury in human cardiomyocytes partially via the miR‑195/RORA axis [
29], it can be inferred that FGD5‑AS1 accelerate growth and block apoptosis of AC16 cells by moderating the miR‑195/RORA axis. For aortic vascular smooth muscle cells, FGD5-AS1 showed an inhibitory effect on cell growth and a promoting effect on apoptosis, which suggests that it plays an important role in cardiovascular diseases such as atherosclerosis. Moreover, overexpression of FGD5-AS1 can attenuate the calcification of HA-VSMCs induced by high glucose, as indicated by decreased ALP activity and OC secretion. Therefore, FGD5-AS1 exhibits a protective role in high glucose-induced injury. This supplied more support to the recognition of FGD5-AS1 as a predictive factor for T2DM-related CVDs.
In addition, FGD5-AS1 showed an additional effect on cell calcification and fibrosis. In high glucose-induced AC16 cells, FGD5-AS1 can reduce the fibrotic factors, indicating its anti-fibrosis role in cardiomyocytes. In high glucose-induced HA-VSMCs, FGD5-AS1 could reduce calcification stimulated by high glucose. The effect of FGD5-AS1 on vascular cells also existed in non-small cell lung cancer cells presenting as FGD5-AS1 downregulation inhibited HUVEC tube formation [
32]. Our findings provide further insight into the function of FGD5-AS1 in VSMC calcification and cardiomyocytes’ fibrotic status under diabetic conditions.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.